Global Anticoagulants Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030
Summary
Anticoagulants, commonly referred to as blood thinners, are substances that prevent or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals such as leeches and mosquitoes, where they help keep the bite area unclotted long enough for the animal to obtain some blood. As a class of medications, anticoagulants are used in therapy for thrombotic disorders. Oral anticoagulants (OACs) are taken by many people in pill or tablet form, and various intravenous anticoagulant dosage forms are used in hospitals. Some anticoagulants are used in medical equipment, such as test tubes, serum-separating tubes, blood transfusion bags, and dialysis equipment.
According to APO Research, The global Anticoagulants market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North American market for Anticoagulants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Anticoagulants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Anticoagulants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Anticoagulants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Anticoagulants include Sanofi, Bristol-Myers Squibb, Bayer, Johnson & Johnson., Genentech (Roche), Boehringer Ingelheim, Lilly, Daiichi Sankyo and Otsuka, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Anticoagulants, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Anticoagulants, also provides the value of main regions and countries. Of the upcoming market potential for Anticoagulants, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Anticoagulants revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Anticoagulants market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Anticoagulants company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Anticoagulants segment by Company
1. To analyze and research the global Anticoagulants status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Anticoagulants key companies, revenue, market share, and recent developments.
3. To split the Anticoagulants breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Anticoagulants market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Anticoagulants significant trends, drivers, influence factors in global and regions.
6. To analyze Anticoagulants competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anticoagulants market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anticoagulants and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anticoagulants.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anticoagulants industry.
Chapter 3: Detailed analysis of Anticoagulants company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Anticoagulants in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Anticoagulants in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Anticoagulants, commonly referred to as blood thinners, are substances that prevent or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals such as leeches and mosquitoes, where they help keep the bite area unclotted long enough for the animal to obtain some blood. As a class of medications, anticoagulants are used in therapy for thrombotic disorders. Oral anticoagulants (OACs) are taken by many people in pill or tablet form, and various intravenous anticoagulant dosage forms are used in hospitals. Some anticoagulants are used in medical equipment, such as test tubes, serum-separating tubes, blood transfusion bags, and dialysis equipment.
According to APO Research, The global Anticoagulants market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North American market for Anticoagulants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Anticoagulants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Anticoagulants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Anticoagulants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Anticoagulants include Sanofi, Bristol-Myers Squibb, Bayer, Johnson & Johnson., Genentech (Roche), Boehringer Ingelheim, Lilly, Daiichi Sankyo and Otsuka, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Anticoagulants, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Anticoagulants, also provides the value of main regions and countries. Of the upcoming market potential for Anticoagulants, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Anticoagulants revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Anticoagulants market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Anticoagulants company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Anticoagulants segment by Company
- Sanofi
- Bristol-Myers Squibb
- Bayer
- Johnson & Johnson.
- Genentech (Roche)
- Boehringer Ingelheim
- Lilly
- Daiichi Sankyo
- Otsuka
- AstraZeneca
- Pfizer
- Aspen
- The Medicines Company
- Platelet Aggregation Inhibitors (PAI)
- Low-Molecular-Weight Heparin (LMWH)
- Direct Thrombin Inhibitor (DTI)
- Direct Factor Xa Inhibitors (DFXa)
- Vitamin K antagonists (VKA)
- Others
- VTE
- ACS/MI
- AF
- Others
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global Anticoagulants status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Anticoagulants key companies, revenue, market share, and recent developments.
3. To split the Anticoagulants breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Anticoagulants market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Anticoagulants significant trends, drivers, influence factors in global and regions.
6. To analyze Anticoagulants competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anticoagulants market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anticoagulants and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anticoagulants.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anticoagulants industry.
Chapter 3: Detailed analysis of Anticoagulants company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Anticoagulants in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Anticoagulants in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Global Anticoagulants Market Size, 2019 VS 2023 VS 2030
1.3 Global Anticoagulants Market Size (2019-2030)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 ANTICOAGULANTS MARKET DYNAMICS
2.1 Anticoagulants Industry Trends
2.2 Anticoagulants Industry Drivers
2.3 Anticoagulants Industry Opportunities and Challenges
2.4 Anticoagulants Industry Restraints
3 ANTICOAGULANTS MARKET BY COMPANY
3.1 Global Anticoagulants Company Revenue Ranking in 2023
3.2 Global Anticoagulants Revenue by Company (2019-2024)
3.3 Global Anticoagulants Company Ranking, 2022 VS 2023 VS 2024
3.4 Global Anticoagulants Company Manufacturing Base & Headquarters
3.5 Global Anticoagulants Company, Product Type & Application
3.6 Global Anticoagulants Company Commercialization Time
3.7 Market Competitive Analysis
3.7.1 Global Anticoagulants Market CR5 and HHI
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.7.3 2023 Anticoagulants Tier 1, Tier 2, and Tier
3.8 Mergers & Acquisitions, Expansion
4 ANTICOAGULANTS MARKET BY TYPE
4.1 Anticoagulants Type Introduction
4.1.1 Platelet Aggregation Inhibitors (PAI)
4.1.2 Low-Molecular-Weight Heparin (LMWH)
4.1.3 Direct Thrombin Inhibitor (DTI)
4.1.4 Direct Factor Xa Inhibitors (DFXa)
4.1.5 Vitamin K antagonists (VKA)
4.1.6 Others
4.2 Global Anticoagulants Sales Value by Type
4.2.1 Global Anticoagulants Sales Value by Type (2019 VS 2023 VS 2030)
4.2.2 Global Anticoagulants Sales Value by Type (2019-2030)
4.2.3 Global Anticoagulants Sales Value Share by Type (2019-2030)
5 ANTICOAGULANTS MARKET BY APPLICATION
5.1 Anticoagulants Application Introduction
5.1.1 VTE
5.1.2 ACS/MI
5.1.3 AF
5.1.4 Others
5.2 Global Anticoagulants Sales Value by Application
5.2.1 Global Anticoagulants Sales Value by Application (2019 VS 2023 VS 2030)
5.2.2 Global Anticoagulants Sales Value by Application (2019-2030)
5.2.3 Global Anticoagulants Sales Value Share by Application (2019-2030)
6 ANTICOAGULANTS MARKET BY REGION
6.1 Global Anticoagulants Sales Value by Region: 2019 VS 2023 VS 2030
6.2 Global Anticoagulants Sales Value by Region (2019-2030)
6.2.1 Global Anticoagulants Sales Value by Region: 2019-2024
6.2.2 Global Anticoagulants Sales Value by Region (2025-2030)
6.3 North America
6.3.1 North America Anticoagulants Sales Value (2019-2030)
6.3.2 North America Anticoagulants Sales Value Share by Country, 2023 VS 2030
6.4 Europe
6.4.1 Europe Anticoagulants Sales Value (2019-2030)
6.4.2 Europe Anticoagulants Sales Value Share by Country, 2023 VS 2030
6.5 Asia-Pacific
6.5.1 Asia-Pacific Anticoagulants Sales Value (2019-2030)
6.5.2 Asia-Pacific Anticoagulants Sales Value Share by Country, 2023 VS 2030
6.6 Latin America
6.6.1 Latin America Anticoagulants Sales Value (2019-2030)
6.6.2 Latin America Anticoagulants Sales Value Share by Country, 2023 VS 2030
6.7 Middle East & Africa
6.7.1 Middle East & Africa Anticoagulants Sales Value (2019-2030)
6.7.2 Middle East & Africa Anticoagulants Sales Value Share by Country, 2023 VS 2030
7 ANTICOAGULANTS MARKET BY COUNTRY
7.1 Global Anticoagulants Sales Value by Country: 2019 VS 2023 VS 2030
7.2 Global Anticoagulants Sales Value by Country (2019-2030)
7.2.1 Global Anticoagulants Sales Value by Country (2019-2024)
7.2.2 Global Anticoagulants Sales Value by Country (2025-2030)
7.3 USA
7.3.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.3.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.3.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.4 Canada
7.4.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.4.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.4.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.5 Germany
7.5.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.5.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.6 France
7.6.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.6.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.7 U.K.
7.7.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.7.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.8 Italy
7.8.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.8.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.9 Netherlands
7.9.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.9.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.10 Nordic Countries
7.10.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.10.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.11 China
7.11.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.11.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.12 Japan
7.12.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.12.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.13 South Korea
7.13.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.13.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.14 Southeast Asia
7.14.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.14.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.15 India
7.15.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.15.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.16 Australia
7.16.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.16.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.17 Mexico
7.17.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.17.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.18 Brazil
7.18.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.18.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.19 Turkey
7.19.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.19.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.20 Saudi Arabia
7.20.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.20.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.21 UAE
7.21.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.21.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 Sanofi
8.1.1 Sanofi Comapny Information
8.1.2 Sanofi Business Overview
8.1.3 Sanofi Anticoagulants Revenue and Gross Margin (2019-2024)
8.1.4 Sanofi Anticoagulants Product Portfolio
8.1.5 Sanofi Recent Developments
8.2 Bristol-Myers Squibb
8.2.1 Bristol-Myers Squibb Comapny Information
8.2.2 Bristol-Myers Squibb Business Overview
8.2.3 Bristol-Myers Squibb Anticoagulants Revenue and Gross Margin (2019-2024)
8.2.4 Bristol-Myers Squibb Anticoagulants Product Portfolio
8.2.5 Bristol-Myers Squibb Recent Developments
8.3 Bayer
8.3.1 Bayer Comapny Information
8.3.2 Bayer Business Overview
8.3.3 Bayer Anticoagulants Revenue and Gross Margin (2019-2024)
8.3.4 Bayer Anticoagulants Product Portfolio
8.3.5 Bayer Recent Developments
8.4 Johnson & Johnson.
8.4.1 Johnson & Johnson. Comapny Information
8.4.2 Johnson & Johnson. Business Overview
8.4.3 Johnson & Johnson. Anticoagulants Revenue and Gross Margin (2019-2024)
8.4.4 Johnson & Johnson. Anticoagulants Product Portfolio
8.4.5 Johnson & Johnson. Recent Developments
8.5 Genentech (Roche)
8.5.1 Genentech (Roche) Comapny Information
8.5.2 Genentech (Roche) Business Overview
8.5.3 Genentech (Roche) Anticoagulants Revenue and Gross Margin (2019-2024)
8.5.4 Genentech (Roche) Anticoagulants Product Portfolio
8.5.5 Genentech (Roche) Recent Developments
8.6 Boehringer Ingelheim
8.6.1 Boehringer Ingelheim Comapny Information
8.6.2 Boehringer Ingelheim Business Overview
8.6.3 Boehringer Ingelheim Anticoagulants Revenue and Gross Margin (2019-2024)
8.6.4 Boehringer Ingelheim Anticoagulants Product Portfolio
8.6.5 Boehringer Ingelheim Recent Developments
8.7 Lilly
8.7.1 Lilly Comapny Information
8.7.2 Lilly Business Overview
8.7.3 Lilly Anticoagulants Revenue and Gross Margin (2019-2024)
8.7.4 Lilly Anticoagulants Product Portfolio
8.7.5 Lilly Recent Developments
8.8 Daiichi Sankyo
8.8.1 Daiichi Sankyo Comapny Information
8.8.2 Daiichi Sankyo Business Overview
8.8.3 Daiichi Sankyo Anticoagulants Revenue and Gross Margin (2019-2024)
8.8.4 Daiichi Sankyo Anticoagulants Product Portfolio
8.8.5 Daiichi Sankyo Recent Developments
8.9 Otsuka
8.9.1 Otsuka Comapny Information
8.9.2 Otsuka Business Overview
8.9.3 Otsuka Anticoagulants Revenue and Gross Margin (2019-2024)
8.9.4 Otsuka Anticoagulants Product Portfolio
8.9.5 Otsuka Recent Developments
8.10 AstraZeneca
8.10.1 AstraZeneca Comapny Information
8.10.2 AstraZeneca Business Overview
8.10.3 AstraZeneca Anticoagulants Revenue and Gross Margin (2019-2024)
8.10.4 AstraZeneca Anticoagulants Product Portfolio
8.10.5 AstraZeneca Recent Developments
8.11 Pfizer
8.11.1 Pfizer Comapny Information
8.11.2 Pfizer Business Overview
8.11.3 Pfizer Anticoagulants Revenue and Gross Margin (2019-2024)
8.11.4 Pfizer Anticoagulants Product Portfolio
8.11.5 Pfizer Recent Developments
8.12 Aspen
8.12.1 Aspen Comapny Information
8.12.2 Aspen Business Overview
8.12.3 Aspen Anticoagulants Revenue and Gross Margin (2019-2024)
8.12.4 Aspen Anticoagulants Product Portfolio
8.12.5 Aspen Recent Developments
8.13 The Medicines Company
8.13.1 The Medicines Company Comapny Information
8.13.2 The Medicines Company Business Overview
8.13.3 The Medicines Company Anticoagulants Revenue and Gross Margin (2019-2024)
8.13.4 The Medicines Company Anticoagulants Product Portfolio
8.13.5 The Medicines Company Recent Developments
9 CONCLUDING INSIGHTS
10 APPENDIX
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
1.1 Product Definition
1.2 Global Anticoagulants Market Size, 2019 VS 2023 VS 2030
1.3 Global Anticoagulants Market Size (2019-2030)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 ANTICOAGULANTS MARKET DYNAMICS
2.1 Anticoagulants Industry Trends
2.2 Anticoagulants Industry Drivers
2.3 Anticoagulants Industry Opportunities and Challenges
2.4 Anticoagulants Industry Restraints
3 ANTICOAGULANTS MARKET BY COMPANY
3.1 Global Anticoagulants Company Revenue Ranking in 2023
3.2 Global Anticoagulants Revenue by Company (2019-2024)
3.3 Global Anticoagulants Company Ranking, 2022 VS 2023 VS 2024
3.4 Global Anticoagulants Company Manufacturing Base & Headquarters
3.5 Global Anticoagulants Company, Product Type & Application
3.6 Global Anticoagulants Company Commercialization Time
3.7 Market Competitive Analysis
3.7.1 Global Anticoagulants Market CR5 and HHI
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.7.3 2023 Anticoagulants Tier 1, Tier 2, and Tier
3.8 Mergers & Acquisitions, Expansion
4 ANTICOAGULANTS MARKET BY TYPE
4.1 Anticoagulants Type Introduction
4.1.1 Platelet Aggregation Inhibitors (PAI)
4.1.2 Low-Molecular-Weight Heparin (LMWH)
4.1.3 Direct Thrombin Inhibitor (DTI)
4.1.4 Direct Factor Xa Inhibitors (DFXa)
4.1.5 Vitamin K antagonists (VKA)
4.1.6 Others
4.2 Global Anticoagulants Sales Value by Type
4.2.1 Global Anticoagulants Sales Value by Type (2019 VS 2023 VS 2030)
4.2.2 Global Anticoagulants Sales Value by Type (2019-2030)
4.2.3 Global Anticoagulants Sales Value Share by Type (2019-2030)
5 ANTICOAGULANTS MARKET BY APPLICATION
5.1 Anticoagulants Application Introduction
5.1.1 VTE
5.1.2 ACS/MI
5.1.3 AF
5.1.4 Others
5.2 Global Anticoagulants Sales Value by Application
5.2.1 Global Anticoagulants Sales Value by Application (2019 VS 2023 VS 2030)
5.2.2 Global Anticoagulants Sales Value by Application (2019-2030)
5.2.3 Global Anticoagulants Sales Value Share by Application (2019-2030)
6 ANTICOAGULANTS MARKET BY REGION
6.1 Global Anticoagulants Sales Value by Region: 2019 VS 2023 VS 2030
6.2 Global Anticoagulants Sales Value by Region (2019-2030)
6.2.1 Global Anticoagulants Sales Value by Region: 2019-2024
6.2.2 Global Anticoagulants Sales Value by Region (2025-2030)
6.3 North America
6.3.1 North America Anticoagulants Sales Value (2019-2030)
6.3.2 North America Anticoagulants Sales Value Share by Country, 2023 VS 2030
6.4 Europe
6.4.1 Europe Anticoagulants Sales Value (2019-2030)
6.4.2 Europe Anticoagulants Sales Value Share by Country, 2023 VS 2030
6.5 Asia-Pacific
6.5.1 Asia-Pacific Anticoagulants Sales Value (2019-2030)
6.5.2 Asia-Pacific Anticoagulants Sales Value Share by Country, 2023 VS 2030
6.6 Latin America
6.6.1 Latin America Anticoagulants Sales Value (2019-2030)
6.6.2 Latin America Anticoagulants Sales Value Share by Country, 2023 VS 2030
6.7 Middle East & Africa
6.7.1 Middle East & Africa Anticoagulants Sales Value (2019-2030)
6.7.2 Middle East & Africa Anticoagulants Sales Value Share by Country, 2023 VS 2030
7 ANTICOAGULANTS MARKET BY COUNTRY
7.1 Global Anticoagulants Sales Value by Country: 2019 VS 2023 VS 2030
7.2 Global Anticoagulants Sales Value by Country (2019-2030)
7.2.1 Global Anticoagulants Sales Value by Country (2019-2024)
7.2.2 Global Anticoagulants Sales Value by Country (2025-2030)
7.3 USA
7.3.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.3.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.3.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.4 Canada
7.4.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.4.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.4.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.5 Germany
7.5.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.5.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.6 France
7.6.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.6.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.7 U.K.
7.7.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.7.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.8 Italy
7.8.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.8.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.9 Netherlands
7.9.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.9.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.10 Nordic Countries
7.10.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.10.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.11 China
7.11.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.11.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.12 Japan
7.12.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.12.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.13 South Korea
7.13.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.13.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.14 Southeast Asia
7.14.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.14.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.15 India
7.15.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.15.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.16 Australia
7.16.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.16.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.17 Mexico
7.17.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.17.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.18 Brazil
7.18.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.18.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.19 Turkey
7.19.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.19.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.20 Saudi Arabia
7.20.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.20.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
7.21 UAE
7.21.1 Global Anticoagulants Sales Value Growth Rate (2019-2030)
7.21.2 Global Anticoagulants Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Anticoagulants Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 Sanofi
8.1.1 Sanofi Comapny Information
8.1.2 Sanofi Business Overview
8.1.3 Sanofi Anticoagulants Revenue and Gross Margin (2019-2024)
8.1.4 Sanofi Anticoagulants Product Portfolio
8.1.5 Sanofi Recent Developments
8.2 Bristol-Myers Squibb
8.2.1 Bristol-Myers Squibb Comapny Information
8.2.2 Bristol-Myers Squibb Business Overview
8.2.3 Bristol-Myers Squibb Anticoagulants Revenue and Gross Margin (2019-2024)
8.2.4 Bristol-Myers Squibb Anticoagulants Product Portfolio
8.2.5 Bristol-Myers Squibb Recent Developments
8.3 Bayer
8.3.1 Bayer Comapny Information
8.3.2 Bayer Business Overview
8.3.3 Bayer Anticoagulants Revenue and Gross Margin (2019-2024)
8.3.4 Bayer Anticoagulants Product Portfolio
8.3.5 Bayer Recent Developments
8.4 Johnson & Johnson.
8.4.1 Johnson & Johnson. Comapny Information
8.4.2 Johnson & Johnson. Business Overview
8.4.3 Johnson & Johnson. Anticoagulants Revenue and Gross Margin (2019-2024)
8.4.4 Johnson & Johnson. Anticoagulants Product Portfolio
8.4.5 Johnson & Johnson. Recent Developments
8.5 Genentech (Roche)
8.5.1 Genentech (Roche) Comapny Information
8.5.2 Genentech (Roche) Business Overview
8.5.3 Genentech (Roche) Anticoagulants Revenue and Gross Margin (2019-2024)
8.5.4 Genentech (Roche) Anticoagulants Product Portfolio
8.5.5 Genentech (Roche) Recent Developments
8.6 Boehringer Ingelheim
8.6.1 Boehringer Ingelheim Comapny Information
8.6.2 Boehringer Ingelheim Business Overview
8.6.3 Boehringer Ingelheim Anticoagulants Revenue and Gross Margin (2019-2024)
8.6.4 Boehringer Ingelheim Anticoagulants Product Portfolio
8.6.5 Boehringer Ingelheim Recent Developments
8.7 Lilly
8.7.1 Lilly Comapny Information
8.7.2 Lilly Business Overview
8.7.3 Lilly Anticoagulants Revenue and Gross Margin (2019-2024)
8.7.4 Lilly Anticoagulants Product Portfolio
8.7.5 Lilly Recent Developments
8.8 Daiichi Sankyo
8.8.1 Daiichi Sankyo Comapny Information
8.8.2 Daiichi Sankyo Business Overview
8.8.3 Daiichi Sankyo Anticoagulants Revenue and Gross Margin (2019-2024)
8.8.4 Daiichi Sankyo Anticoagulants Product Portfolio
8.8.5 Daiichi Sankyo Recent Developments
8.9 Otsuka
8.9.1 Otsuka Comapny Information
8.9.2 Otsuka Business Overview
8.9.3 Otsuka Anticoagulants Revenue and Gross Margin (2019-2024)
8.9.4 Otsuka Anticoagulants Product Portfolio
8.9.5 Otsuka Recent Developments
8.10 AstraZeneca
8.10.1 AstraZeneca Comapny Information
8.10.2 AstraZeneca Business Overview
8.10.3 AstraZeneca Anticoagulants Revenue and Gross Margin (2019-2024)
8.10.4 AstraZeneca Anticoagulants Product Portfolio
8.10.5 AstraZeneca Recent Developments
8.11 Pfizer
8.11.1 Pfizer Comapny Information
8.11.2 Pfizer Business Overview
8.11.3 Pfizer Anticoagulants Revenue and Gross Margin (2019-2024)
8.11.4 Pfizer Anticoagulants Product Portfolio
8.11.5 Pfizer Recent Developments
8.12 Aspen
8.12.1 Aspen Comapny Information
8.12.2 Aspen Business Overview
8.12.3 Aspen Anticoagulants Revenue and Gross Margin (2019-2024)
8.12.4 Aspen Anticoagulants Product Portfolio
8.12.5 Aspen Recent Developments
8.13 The Medicines Company
8.13.1 The Medicines Company Comapny Information
8.13.2 The Medicines Company Business Overview
8.13.3 The Medicines Company Anticoagulants Revenue and Gross Margin (2019-2024)
8.13.4 The Medicines Company Anticoagulants Product Portfolio
8.13.5 The Medicines Company Recent Developments
9 CONCLUDING INSIGHTS
10 APPENDIX
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
LIST OF TABLES
Table 1. Anticoagulants Industry Trends
Table 2. Anticoagulants Industry Drivers
Table 3. Anticoagulants Industry Opportunities and Challenges
Table 4. Anticoagulants Industry Restraints
Table 5. Global Anticoagulants Revenue by Company (US$ Million) & (2019-2024)
Table 6. Global Anticoagulants Revenue Share by Company (2019-2024)
Table 7. Global Anticoagulants Company Ranking, 2022 VS 2023 VS 2024 & (US$ Million)
Table 8. Global Anticoagulants Key Company Manufacturing Base & Headquarters
Table 9. Global Anticoagulants Company, Product Type & Application
Table 10. Global Anticoagulants Company Commercialization Time
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Anticoagulants by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Major Companies of Platelet Aggregation Inhibitors (PAI)
Table 15. Major Companies of Low-Molecular-Weight Heparin (LMWH)
Table 16. Major Companies of Direct Thrombin Inhibitor (DTI)
Table 17. Major Companies of Direct Factor Xa Inhibitors (DFXa)
Table 18. Major Companies of Vitamin K antagonists (VKA)
Table 19. Major Companies of Others
Table 20. Global Anticoagulants Sales Value by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 21. Global Anticoagulants Sales Value by Type (2019-2024) & (US$ Million)
Table 22. Global Anticoagulants Sales Value by Type (2025-2030) & (US$ Million)
Table 23. Global Anticoagulants Sales Value Share by Type (2019-2024)
Table 24. Global Anticoagulants Sales Value Share by Type (2025-2030)
Table 25. Major Companies of VTE
Table 26. Major Companies of ACS/MI
Table 27. Major Companies of AF
Table 28. Major Companies of Others
Table 29. Global Anticoagulants Sales Value by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 30. Global Anticoagulants Sales Value by Application (2019-2024) & (US$ Million)
Table 31. Global Anticoagulants Sales Value by Application (2025-2030) & (US$ Million)
Table 32. Global Anticoagulants Sales Value Share by Application (2019-2024)
Table 33. Global Anticoagulants Sales Value Share by Application (2025-2030)
Table 34. Global Anticoagulants Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 35. Global Anticoagulants Sales Value by Region (2019-2024) & (US$ Million)
Table 36. Global Anticoagulants Sales Value Share by Region (2019-2024)
Table 37. Global Anticoagulants Sales Value by Region (2025-2030) & (US$ Million)
Table 38. Global Anticoagulants Sales Value Share by Region (2025-2030)
Table 39. Global Anticoagulants Sales Value by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 40. Global Anticoagulants Sales Value by Country (2019-2024) & (US$ Million)
Table 41. Global Anticoagulants Sales Value Market Share by Country (2019-2024)
Table 42. Global Anticoagulants Sales Value by Country (2025-2030) & (US$ Million)
Table 43. Global Anticoagulants Sales Value Market Share by Country (2025-2030)
Table 44. Sanofi Company Information
Table 45. Sanofi Business Overview
Table 46. Sanofi Anticoagulants Revenue (US$ Million) and Gross Margin (2019-2024)
Table 47. Sanofi Anticoagulants Product Portfolio
Table 48. Sanofi Recent Development
Table 49. Bristol-Myers Squibb Company Information
Table 50. Bristol-Myers Squibb Business Overview
Table 51. Bristol-Myers Squibb Anticoagulants Revenue (US$ Million) and Gross Margin (2019-2024)
Table 52. Bristol-Myers Squibb Anticoagulants Product Portfolio
Table 53. Bristol-Myers Squibb Recent Development
Table 54. Bayer Company Information
Table 55. Bayer Business Overview
Table 56. Bayer Anticoagulants Revenue (US$ Million) and Gross Margin (2019-2024)
Table 57. Bayer Anticoagulants Product Portfolio
Table 58. Bayer Recent Development
Table 59. Johnson & Johnson. Company Information
Table 60. Johnson & Johnson. Business Overview
Table 61. Johnson & Johnson. Anticoagulants Revenue (US$ Million) and Gross Margin (2019-2024)
Table 62. Johnson & Johnson. Anticoagulants Product Portfolio
Table 63. Johnson & Johnson. Recent Development
Table 64. Genentech (Roche) Company Information
Table 65. Genentech (Roche) Business Overview
Table 66. Genentech (Roche) Anticoagulants Revenue (US$ Million) and Gross Margin (2019-2024)
Table 67. Genentech (Roche) Anticoagulants Product Portfolio
Table 68. Genentech (Roche) Recent Development
Table 69. Boehringer Ingelheim Company Information
Table 70. Boehringer Ingelheim Business Overview
Table 71. Boehringer Ingelheim Anticoagulants Revenue (US$ Million) and Gross Margin (2019-2024)
Table 72. Boehringer Ingelheim Anticoagulants Product Portfolio
Table 73. Boehringer Ingelheim Recent Development
Table 74. Lilly Company Information
Table 75. Lilly Business Overview
Table 76. Lilly Anticoagulants Revenue (US$ Million) and Gross Margin (2019-2024)
Table 77. Lilly Anticoagulants Product Portfolio
Table 78. Lilly Recent Development
Table 79. Daiichi Sankyo Company Information
Table 80. Daiichi Sankyo Business Overview
Table 81. Daiichi Sankyo Anticoagulants Revenue (US$ Million) and Gross Margin (2019-2024)
Table 82. Daiichi Sankyo Anticoagulants Product Portfolio
Table 83. Daiichi Sankyo Recent Development
Table 84. Otsuka Company Information
Table 85. Otsuka Business Overview
Table 86. Otsuka Anticoagulants Revenue (US$ Million) and Gross Margin (2019-2024)
Table 87. Otsuka Anticoagulants Product Portfolio
Table 88. Otsuka Recent Development
Table 89. AstraZeneca Company Information
Table 90. AstraZeneca Business Overview
Table 91. AstraZeneca Anticoagulants Revenue (US$ Million) and Gross Margin (2019-2024)
Table 92. AstraZeneca Anticoagulants Product Portfolio
Table 93. AstraZeneca Recent Development
Table 94. Pfizer Company Information
Table 95. Pfizer Business Overview
Table 96. Pfizer Anticoagulants Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 97. Pfizer Anticoagulants Product Portfolio
Table 98. Pfizer Recent Development
Table 99. Aspen Company Information
Table 100. Aspen Business Overview
Table 101. Aspen Anticoagulants Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 102. Aspen Anticoagulants Product Portfolio
Table 103. Aspen Recent Development
Table 104. The Medicines Company Company Information
Table 105. The Medicines Company Business Overview
Table 106. The Medicines Company Anticoagulants Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 107. The Medicines Company Anticoagulants Product Portfolio
Table 108. The Medicines Company Recent Development
Table 109. Research Programs/Design for This Report
Table 110. Authors List of This Report
Table 111. Secondary Sources
Table 112. Primary Sources
Table 1. Anticoagulants Industry Trends
Table 2. Anticoagulants Industry Drivers
Table 3. Anticoagulants Industry Opportunities and Challenges
Table 4. Anticoagulants Industry Restraints
Table 5. Global Anticoagulants Revenue by Company (US$ Million) & (2019-2024)
Table 6. Global Anticoagulants Revenue Share by Company (2019-2024)
Table 7. Global Anticoagulants Company Ranking, 2022 VS 2023 VS 2024 & (US$ Million)
Table 8. Global Anticoagulants Key Company Manufacturing Base & Headquarters
Table 9. Global Anticoagulants Company, Product Type & Application
Table 10. Global Anticoagulants Company Commercialization Time
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Anticoagulants by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Major Companies of Platelet Aggregation Inhibitors (PAI)
Table 15. Major Companies of Low-Molecular-Weight Heparin (LMWH)
Table 16. Major Companies of Direct Thrombin Inhibitor (DTI)
Table 17. Major Companies of Direct Factor Xa Inhibitors (DFXa)
Table 18. Major Companies of Vitamin K antagonists (VKA)
Table 19. Major Companies of Others
Table 20. Global Anticoagulants Sales Value by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 21. Global Anticoagulants Sales Value by Type (2019-2024) & (US$ Million)
Table 22. Global Anticoagulants Sales Value by Type (2025-2030) & (US$ Million)
Table 23. Global Anticoagulants Sales Value Share by Type (2019-2024)
Table 24. Global Anticoagulants Sales Value Share by Type (2025-2030)
Table 25. Major Companies of VTE
Table 26. Major Companies of ACS/MI
Table 27. Major Companies of AF
Table 28. Major Companies of Others
Table 29. Global Anticoagulants Sales Value by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 30. Global Anticoagulants Sales Value by Application (2019-2024) & (US$ Million)
Table 31. Global Anticoagulants Sales Value by Application (2025-2030) & (US$ Million)
Table 32. Global Anticoagulants Sales Value Share by Application (2019-2024)
Table 33. Global Anticoagulants Sales Value Share by Application (2025-2030)
Table 34. Global Anticoagulants Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 35. Global Anticoagulants Sales Value by Region (2019-2024) & (US$ Million)
Table 36. Global Anticoagulants Sales Value Share by Region (2019-2024)
Table 37. Global Anticoagulants Sales Value by Region (2025-2030) & (US$ Million)
Table 38. Global Anticoagulants Sales Value Share by Region (2025-2030)
Table 39. Global Anticoagulants Sales Value by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 40. Global Anticoagulants Sales Value by Country (2019-2024) & (US$ Million)
Table 41. Global Anticoagulants Sales Value Market Share by Country (2019-2024)
Table 42. Global Anticoagulants Sales Value by Country (2025-2030) & (US$ Million)
Table 43. Global Anticoagulants Sales Value Market Share by Country (2025-2030)
Table 44. Sanofi Company Information
Table 45. Sanofi Business Overview
Table 46. Sanofi Anticoagulants Revenue (US$ Million) and Gross Margin (2019-2024)
Table 47. Sanofi Anticoagulants Product Portfolio
Table 48. Sanofi Recent Development
Table 49. Bristol-Myers Squibb Company Information
Table 50. Bristol-Myers Squibb Business Overview
Table 51. Bristol-Myers Squibb Anticoagulants Revenue (US$ Million) and Gross Margin (2019-2024)
Table 52. Bristol-Myers Squibb Anticoagulants Product Portfolio
Table 53. Bristol-Myers Squibb Recent Development
Table 54. Bayer Company Information
Table 55. Bayer Business Overview
Table 56. Bayer Anticoagulants Revenue (US$ Million) and Gross Margin (2019-2024)
Table 57. Bayer Anticoagulants Product Portfolio
Table 58. Bayer Recent Development
Table 59. Johnson & Johnson. Company Information
Table 60. Johnson & Johnson. Business Overview
Table 61. Johnson & Johnson. Anticoagulants Revenue (US$ Million) and Gross Margin (2019-2024)
Table 62. Johnson & Johnson. Anticoagulants Product Portfolio
Table 63. Johnson & Johnson. Recent Development
Table 64. Genentech (Roche) Company Information
Table 65. Genentech (Roche) Business Overview
Table 66. Genentech (Roche) Anticoagulants Revenue (US$ Million) and Gross Margin (2019-2024)
Table 67. Genentech (Roche) Anticoagulants Product Portfolio
Table 68. Genentech (Roche) Recent Development
Table 69. Boehringer Ingelheim Company Information
Table 70. Boehringer Ingelheim Business Overview
Table 71. Boehringer Ingelheim Anticoagulants Revenue (US$ Million) and Gross Margin (2019-2024)
Table 72. Boehringer Ingelheim Anticoagulants Product Portfolio
Table 73. Boehringer Ingelheim Recent Development
Table 74. Lilly Company Information
Table 75. Lilly Business Overview
Table 76. Lilly Anticoagulants Revenue (US$ Million) and Gross Margin (2019-2024)
Table 77. Lilly Anticoagulants Product Portfolio
Table 78. Lilly Recent Development
Table 79. Daiichi Sankyo Company Information
Table 80. Daiichi Sankyo Business Overview
Table 81. Daiichi Sankyo Anticoagulants Revenue (US$ Million) and Gross Margin (2019-2024)
Table 82. Daiichi Sankyo Anticoagulants Product Portfolio
Table 83. Daiichi Sankyo Recent Development
Table 84. Otsuka Company Information
Table 85. Otsuka Business Overview
Table 86. Otsuka Anticoagulants Revenue (US$ Million) and Gross Margin (2019-2024)
Table 87. Otsuka Anticoagulants Product Portfolio
Table 88. Otsuka Recent Development
Table 89. AstraZeneca Company Information
Table 90. AstraZeneca Business Overview
Table 91. AstraZeneca Anticoagulants Revenue (US$ Million) and Gross Margin (2019-2024)
Table 92. AstraZeneca Anticoagulants Product Portfolio
Table 93. AstraZeneca Recent Development
Table 94. Pfizer Company Information
Table 95. Pfizer Business Overview
Table 96. Pfizer Anticoagulants Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 97. Pfizer Anticoagulants Product Portfolio
Table 98. Pfizer Recent Development
Table 99. Aspen Company Information
Table 100. Aspen Business Overview
Table 101. Aspen Anticoagulants Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 102. Aspen Anticoagulants Product Portfolio
Table 103. Aspen Recent Development
Table 104. The Medicines Company Company Information
Table 105. The Medicines Company Business Overview
Table 106. The Medicines Company Anticoagulants Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 107. The Medicines Company Anticoagulants Product Portfolio
Table 108. The Medicines Company Recent Development
Table 109. Research Programs/Design for This Report
Table 110. Authors List of This Report
Table 111. Secondary Sources
Table 112. Primary Sources
LIST OF FIGURES
Figure 1. Anticoagulants Product Picture
Figure 2. Global Anticoagulants Market Size (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Anticoagulants Market Size (2019-2030) & (US$ Million)
Figure 4. Global Anticoagulants Company Revenue Ranking in 2023 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 7. Platelet Aggregation Inhibitors (PAI) Picture
Figure 8. Low-Molecular-Weight Heparin (LMWH) Picture
Figure 9. Direct Thrombin Inhibitor (DTI) Picture
Figure 10. Direct Factor Xa Inhibitors (DFXa) Picture
Figure 11. Vitamin K antagonists (VKA) Picture
Figure 12. Others Picture
Figure 13. Global Anticoagulants Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Anticoagulants Sales Value Share 2019 VS 2023 VS 2030
Figure 15. Global Anticoagulants Sales Value Share by Type (2019-2030)
Figure 16. VTE Picture
Figure 17. ACS/MI Picture
Figure 18. AF Picture
Figure 19. Others Picture
Figure 20. Global Anticoagulants Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 21. Global Anticoagulants Sales Value Share 2019 VS 2023 VS 2030
Figure 22. Global Anticoagulants Sales Value Share by Application (2019-2030)
Figure 23. Global Anticoagulants Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 24. Global Anticoagulants Sales Value Share by Region: 2019 VS 2023 VS 2030
Figure 25. North America Anticoagulants Sales Value (2019-2030) & (US$ Million)
Figure 26. North America Anticoagulants Sales Value Share by Country (%), 2023 VS 2030
Figure 27. Europe Anticoagulants Sales Value (2019-2030) & (US$ Million)
Figure 28. Europe Anticoagulants Sales Value Share by Country (%), 2023 VS 2030
Figure 29. Asia-Pacific Anticoagulants Sales Value (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Anticoagulants Sales Value Share by Country (%), 2023 VS 2030
Figure 31. Latin America Anticoagulants Sales Value (2019-2030) & (US$ Million)
Figure 32. Latin America Anticoagulants Sales Value Share by Country (%), 2023 VS 2030
Figure 33. Middle East & Africa Anticoagulants Sales Value (2019-2030) & (US$ Million)
Figure 34. Middle East & Africa Anticoagulants Sales Value Share by Country (%), 2023 VS 2030
Figure 35. USA Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 36. USA Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 37. USA Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 38. Canada Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 39. Canada Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 40. Canada Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 41. Germany Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 42. Germany Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 43. Germany Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 44. France Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 45. France Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 46. France Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 47. U.K. Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 48. U.K. Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 49. U.K. Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 50. Italy Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 51. Italy Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 52. Italy Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 53. Netherlands Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 54. Netherlands Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 55. Netherlands Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 56. Nordic Countries Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 57. Nordic Countries Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 58. Nordic Countries Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 59. China Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 60. China Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 61. China Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 62. Japan Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 63. Japan Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 64. Japan Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 65. South Korea Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 66. South Korea Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 67. South Korea Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 68. Southeast Asia Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 69. Southeast Asia Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 70. Southeast Asia Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 71. India Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 72. India Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 73. India Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 74. Australia Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 75. Australia Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 76. Australia Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 77. Mexico Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 78. Mexico Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 79. Mexico Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 80. Brazil Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 81. Brazil Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 82. Brazil Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 83. Turkey Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 84. Turkey Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 85. Turkey Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 86. Saudi Arabia Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 87. Saudi Arabia Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 88. Saudi Arabia Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 89. UAE Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 90. UAE Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 91. UAE Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 92. Years Considered
Figure 93. Research Process
Figure 94. Key Executives Interviewed
Figure 1. Anticoagulants Product Picture
Figure 2. Global Anticoagulants Market Size (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Anticoagulants Market Size (2019-2030) & (US$ Million)
Figure 4. Global Anticoagulants Company Revenue Ranking in 2023 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 7. Platelet Aggregation Inhibitors (PAI) Picture
Figure 8. Low-Molecular-Weight Heparin (LMWH) Picture
Figure 9. Direct Thrombin Inhibitor (DTI) Picture
Figure 10. Direct Factor Xa Inhibitors (DFXa) Picture
Figure 11. Vitamin K antagonists (VKA) Picture
Figure 12. Others Picture
Figure 13. Global Anticoagulants Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Anticoagulants Sales Value Share 2019 VS 2023 VS 2030
Figure 15. Global Anticoagulants Sales Value Share by Type (2019-2030)
Figure 16. VTE Picture
Figure 17. ACS/MI Picture
Figure 18. AF Picture
Figure 19. Others Picture
Figure 20. Global Anticoagulants Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 21. Global Anticoagulants Sales Value Share 2019 VS 2023 VS 2030
Figure 22. Global Anticoagulants Sales Value Share by Application (2019-2030)
Figure 23. Global Anticoagulants Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 24. Global Anticoagulants Sales Value Share by Region: 2019 VS 2023 VS 2030
Figure 25. North America Anticoagulants Sales Value (2019-2030) & (US$ Million)
Figure 26. North America Anticoagulants Sales Value Share by Country (%), 2023 VS 2030
Figure 27. Europe Anticoagulants Sales Value (2019-2030) & (US$ Million)
Figure 28. Europe Anticoagulants Sales Value Share by Country (%), 2023 VS 2030
Figure 29. Asia-Pacific Anticoagulants Sales Value (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Anticoagulants Sales Value Share by Country (%), 2023 VS 2030
Figure 31. Latin America Anticoagulants Sales Value (2019-2030) & (US$ Million)
Figure 32. Latin America Anticoagulants Sales Value Share by Country (%), 2023 VS 2030
Figure 33. Middle East & Africa Anticoagulants Sales Value (2019-2030) & (US$ Million)
Figure 34. Middle East & Africa Anticoagulants Sales Value Share by Country (%), 2023 VS 2030
Figure 35. USA Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 36. USA Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 37. USA Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 38. Canada Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 39. Canada Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 40. Canada Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 41. Germany Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 42. Germany Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 43. Germany Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 44. France Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 45. France Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 46. France Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 47. U.K. Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 48. U.K. Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 49. U.K. Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 50. Italy Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 51. Italy Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 52. Italy Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 53. Netherlands Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 54. Netherlands Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 55. Netherlands Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 56. Nordic Countries Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 57. Nordic Countries Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 58. Nordic Countries Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 59. China Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 60. China Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 61. China Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 62. Japan Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 63. Japan Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 64. Japan Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 65. South Korea Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 66. South Korea Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 67. South Korea Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 68. Southeast Asia Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 69. Southeast Asia Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 70. Southeast Asia Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 71. India Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 72. India Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 73. India Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 74. Australia Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 75. Australia Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 76. Australia Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 77. Mexico Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 78. Mexico Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 79. Mexico Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 80. Brazil Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 81. Brazil Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 82. Brazil Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 83. Turkey Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 84. Turkey Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 85. Turkey Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 86. Saudi Arabia Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 87. Saudi Arabia Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 88. Saudi Arabia Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 89. UAE Anticoagulants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 90. UAE Anticoagulants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 91. UAE Anticoagulants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 92. Years Considered
Figure 93. Research Process
Figure 94. Key Executives Interviewed
